Glioma Care

Personalized treatment strategies for glioma and that has returned after prior therapy

Overview

Glioma is the most lethal tumor of brain tumor in adults. Recurrent glioma refers to a glioma that returns or progresses after previous treatment. This is especially common in high-grade gliomas, where tumor cells may remain within surrounding brain tissue despite surgery, radiotherapy, and chemotherapy.

Key Facts

Incidence

Glioma occurs at roughly 5-10 per 100,000 people per year in U.S. and China registry data.

Symptoms

Headache, seizures, weakness, speech difficulty, memory decline, and changes in balance or vision may occur depending on tumor location.

Diagnosis

Evaluation typically includes contrast-enhanced MRI, review of prior treatment, and in selected cases repeat surgery or biopsy for pathology and molecular testing.

Treatment Options

Our center provides world-class, comprehensive treatment options for recurrent glioma:

• Advanced Repeat Surgery: Our highly skilled neurosurgeons offer unmatched surgical advantages, employing advanced microsurgical techniques, awake surgery and endoscopy surgery to safely maximize tumor resection while protecting critical neurological functions.
• Precision Radiotherapy: We bring extensive clinical experience in re-irradiation, utilizing highly conformal techniques to target recurring tumors precisely while sparing healthy tissue.
• Systemic & Chemotherapy Leadership: Our team proudly led the post-market clinical trials for Temozolomide in China, reflecting our deep expertise and authoritative experience in optimizing chemotherapy regimens.
• First-in-Class Targeted Therapy (Vebreltinib): We are pioneers in targeted therapies. Our team developed the world's first targeted drug for glioma—Vebreltinib. Currently, this breakthrough medication is exclusively launched in China and remains unavailable abroad.
• Tris-CART & Immunotherapy: We harness the power of the immune system through advanced immunotherapies, including our self-developed Tris-CART therapy.
• Innovative Resistance-Overcoming Strategy: Our latest therapeutic breakthrough overcomes the blood-brain barrier to deliver potent treatments directly to the tumor microenvironment.

Recurrence Tendency

High-grade gliomas have a strong tendency to recur, so treatment at recurrence focuses on disease control, neurological function, and quality of life.